Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Creon (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.
• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Improvement in Quality of Life (QoL) and Symptoms: Pancreatic enzyme replacement therapy (PERT) significantly improved quality of life and reduced symptoms related to pancreatic exocrine insufficiency (PEI), particularly in patients with chronic pancreatitis.
• Effectiveness in Malabsorption and Weight Maintenance: PERT was effective in improving malabsorption and supporting weight maintenance across various conditions, including cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-surgical states.
• Potential Impact on Survival: While some small retrospective studies suggested that PERT might positively impact survival, conclusive long-term studies are lacking to firmly establish this effect.
• Safety Information: There is no safety information available in the reviewed studies regarding pancreatic enzyme replacement therapy (PERT).
• Subgroup Findings: Pancreatic enzyme replacement therapy (PERT) demonstrated effectiveness in improving malabsorption and weight maintenance across various subgroups, including patients with cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-surgical states. In patients with chronic pancreatitis, PERT also improved PEI-related symptoms and quality of life. However, the study did not provide details on safety outcomes or comparisons with other treatments, and long-term survival benefits remain inconclusive.